Chinare Pharma (03320.HK) announced that its pharmaceutical commerce under Chinare Pharma has officially signed a strategic cooperation agreement with Pfizer Investment Limited. Both parties will fully leverage their respective strengths to jointly promote the commercial operation of four high-quality mature drugs for lung cancer and breast cancer — Aromasin, Ibrance, Pharmorubicin RD, and Xalkori, expanding patient access.
華潤醫藥(03320.HK)旗下華潤醫藥商業與輝瑞達成戰略合作
Chinares pharma (03320.HK) has reached a strategic cooperation with pfizer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated